Sekundum Atriyal Septal Defektli Çocuklarda Galektin-3

Year 2023, Volume: 8 Issue: 4, 33 - 37, 05.12.2023

Fatma Özkul Mustafa Argun Süleyman Sunkak Derya Koçer

https://doi.org/10.55694/jamer.1365421

Abstract

Amaç: Pediatrik popülasyonda galektin-3’ün kardiyak biyobelirteç olarak rolüne ilişkin sınırlı sayıda çalışma bulunmaktadır. Sekundum atriyal septal defekti (ASD) olan çocuklarda galektin-3 düzeyini ve bunun B-tip natriüretik peptidinin N-terminal prohormonu (NT-proBNP) ile ilişkisini araştırmayı amaçladık.

Gereç ve Yöntemler: Hasta grubunu sekundum ASD’li 27 hasta oluşturdu. Kontrol grubunu benzer yaş ve cinsiyette 30 sağlıklı çocuk oluşturdu. Transtorasik ekokardiyografi ile herhangi bir pencereden ölçülen en büyük ASD çapı ASD boyutu olarak kaydedildi. NT-ProBNP ve galektin-3 için kan örnekleri toplandı.

Bulgular: Sekundum ASD’li çocukların NT-ProBNP düzeyleri sağlıklı çocuklara göre anlamlı derecede yüksekti (p=0.003). Sekundum ASD’li çocukların galektin-3 düzeyleri sağlıklı çocuklarla benzerdi (p=0.377). Sekundum ASD’li çocuklarda galektin-3 ile NT-ProBNP düzeyleri arasında istatistiksel olarak önemli pozitif korelasyon mevcuttu (rho=0.454, p=0.017). Galektin-3 eğrisi altında kalan alan istatistiksel olarak anlamlı değildi (AUC=0.537; p=0.643).

Sonuç: Sekundum ASD’li hastalarda NT-ProBNP düzeyinde artış olmasına rağmen galektin-3 düzeyinde değişiklik olmadı. NT-ProBNP, sekundum ASD’nin tahmini için değerli bir biyobelirteç olmasına rağmen, galektin-3’ün bu hastalığı öngörmede rolü yoktu.

Keywords

Sekundum atriyal septal defekt, galektin-3, B-tip natriüretik peptidinin N-terminal prohormonu, çocuk

Ethical Statement

Çalışma, Sağlık Bilimleri Üniversitesi Kayseri Şehir Eğitim ve Araştırma Hastanesi Çocuk Sağlığı ve Hastalıkları Anabilim Dalı’nda Haziran 2020 – Ocak 2021 tarihleri arasında gerçekleştirildi. Kayseri Şehir Hastanesi Klinik Araştırmalar Etik Kurulu tarafından 30.04.2020 tarihli ve 43 nolu kararı ile uygun görüldü. Çalışmaya alınan tüm hasta ve kontrol grubu çocukların aileleri bilgilendirilerek aydınlatılmış onamları alındı

Supporting Institution

yok

Project Number

43

Galectin-3 in Children with Secundum Atrial Septal Defect

Abstract

Aim: There is a limited number of studies on the role of galectin-3 as a cardiac biomarker in the pediatric population. We aimed to investigate galectin-3 level and its relationship with N-terminal prohormone of brain natriuretic peptide (NT-proBNP) in children with secundum atrial septal defect (ASD).

Material and Methods: Twenty-seven patients with secundum ASD formed the patient group. Thirty healthy children of similar age and gender formed the control group. The largest ASD diameter measured from any window with transthoracic echocardiography was recorded as the ASD size. Blood samples were collected for NT-ProBNP and galectin-3.

Results: Children with secundum ASD had significantly higher NT-ProBNP levels compared with the healthy children (p=0.003). Galectin-3 levels of children with secundum ASD were similar to those of the healthy children (p=0.377). There was a statistically positive correlation between galectin-3 and NT-ProBNP levels in children with secundum ASD (rho=0.454, p=0.017). The area under the curve of galectin-3 was not statistically significant (AUC=0.537; p=0.643).

Conclusion: Although there was an increase in NT-ProBNP level in patients with secundum ASD, galectin-3 level did not change. Although NT-ProBNP was a valuable biomarker for the prediction of secundum ASD, galectin-3 had no role in predicting this disease.

Keywords

secundum atrial septal defect, galectin-3, N-terminal prohormone of brain natriuretic peptide, child

Project Number

43

References

• 1. Geva T, Martins JD, Wald RM. Atrial septal defects. Lancet 2014; 383(9932):1921-32. doi: 10.1016/S0140-6736(13)62145-5.
• 2. Narin N, Baykan A, Argun M, Ozyurt A, Pamukcu O, Bayram A et al. New modified balloon-assisted technique to provide appropriate deployment in the closure of large secundum atrial septal defect using amplatzer septal occluder in children. J Invasive Cardiol. 2014
• 3. Smereczyńska-Wierzbicka E, Pietrzak R, Werner B. A scoping review of galectin-3 as a biomarker of cardiovascular diseases in pediatric populations. Int J Environ Res Public Health 2022; 19(7):4349. doi: 10.3390/ijerph19074349.
• 4. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/ AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013 Oct 15;128(16):e240-327. doi:10.1161/CIR.0b013e31829e8776.
• 5. Gehlken C, Suthahar N, Meijers WC, de Boer RA. Galectin-3 in heart failure: An update of the last 3 years. Heart Fail Clin 2018; 14(1):75–92. doi:10.1002/ehf2.13366
• 6. Baggen VJM, van den Bosch AE, Eindhoven JA, Menting ME, Witsenburg M, Cuypers JAAE, et al. Prognostic value of galectin-3 in adults with congenital heart disease. Heart. 2018 Mar;104(5):394- 400. doi: 10.1136/heartjnl-2017-312070.
• 7. Parker DM, Everett AD, Stabler ME, Vricella L, Jacobs ML, Jacobs JP, et al. Novel Biomarkers Improve prediction of 365-day readmission after pediatric congenital heart surgery. Ann Thorac Surg. 2020 Jan;109(1):164-70. doi: 10.1016/j.athoracsur.2019.05.070.
• 8. Saleh N, Khattab A, Rizk M, Salem S, Abo-Haded H. Value of galectin-3 assay in children with heart failure secondary to congenital heart diseases: A prospective study. BMC Pediatr 2020; 20(1):1–9. ref doi--doi: 10.1186/s12887-020-02427-9.
• 9. Kotby AA, Youssef OI, Elmaraghy MO, El Sharkawy OS. Galectin-3 in children with chronic heart failure with normal and reduced ejection fraction: relationship to disease severity. Pediatr Cardiol 2017; 38(1):95–102. doi: 10.1007/s00246-016-1488-2.
• 10. Elhewala AAS, Ibrahem MM, Hafez ESA. Galectin-3 as a biomarker of heart failure in children with congenital heart disease. Egypt J Hosp Med. 2020; 80(3):1008-13. doi: 10.21608/EJHM.2020.106017
• 11. Cura C, Argun M, Koçer D. Aldosterone, galectin-3, and NTproBNP levels and their values as biomarkers in infants with ventricular septal defect. Turk Kardiyol Dern Ars. 2022; 50(2):131–6. doi: 10.5543/tkda.2022.71734.
• 12. Layla AM, Hussien Neama R. Galectin-3 as early detector of heart failure in children with congenital acyanotic heart disease. Clin Med Diagn 2014; 4(5): 90–8.
• 13. Frank BS, Urban TT, Lewis K, Tong S, Cassidy C, Mitchell MB, et al. Circulating biomarkers of left ventricular hypertrophy in pediatric coarctation of the aorta. Congenit Heart Dis. 2019 May;14(3):446- 53. doi: 10.1111/chd.12744.
• 14. Zegelbone PM, Ringel RE, Coulson JD, Nies MK, Stabler ME, Brown JR, Everett AD. Heart failure biomarker levels correlate with invasive haemodynamics in pulmonary valve replacement. Cardiol Young. 2020 Jan;30(1):50-4. doi: 10.1017/S1047951119002737.
• 15. van den Bosch E, Bossers SSM, Kamphuis VP, Boersma E, Roos-Hesselink JW, Breur JMPJ, et al. Associations between blood biomarkers, cardiac function, and adverse outcome in a young fontan cohort. J Am Heart Assoc. 2021 Feb;10(5):e015022. doi: 10.1161/JAHA.119.015022.